Legend Biotech to Present Positive Early Data for Solid Tumor CAR-T (LB2102) and New CARVYKTI® Analyses at ASCO

summarizeSummary

Legend Biotech announced it will present preliminary Phase 1 data for its investigational solid tumor CAR-T therapy, LB2102, showing early evidence of activity, alongside new analyses for its blockbuster multiple myeloma drug, CARVYKTI®, at the upcoming ASCO Annual Meeting.

check_boxKey Events

• Preliminary Phase 1 Data for LB2102

  Legend Biotech will present preliminary Phase 1 data for LB2102, its investigational DLL3-targeted CAR-T therapy for relapsed/refractory small-cell lung cancer and large-cell neuroendocrine carcinoma, showing early evidence of activity and a manageable safety profile. This marks progress in extending CAR-T approaches into solid tumors.

• New CARVYKTI® Data at ASCO

  The company will present new data on CARVYKTI® (cilta-cel) from the CARTITUDE-4 study, including a cytogenetic subgroup analysis, and a multi-study analysis on immune effector cell-associated enterocolitis (IEC-EC), further reinforcing its clinical profile in multiple myeloma.

• Investor Webcast Event

  Legend Biotech will host a live webcast event for investors on May 31, 2026, during ASCO, to discuss how CARVYKTI® is transforming the multiple myeloma treatment landscape.

auto_awesomeAnalysis

This filing highlights Legend Biotech's pipeline progress in expanding CAR-T therapies into solid tumors with promising early Phase 1 data for LB2102. Simultaneously, new data for the already successful CARVYKTI® reinforces its efficacy and safety profile, supporting its continued market leadership in multiple myeloma. These presentations at a major oncology conference underscore the company's ongoing innovation and potential for future growth drivers.